Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment

Bibliographic Details
Main Authors:	Taylor C. Duke, MD, Ranjit Nair, MD, Carlos Torres-Cabala, MD, Rodabe N. Amaria, MD, Elizabeth Keiser, MD, Roberto Miranda, MD, Swaminathan P. Iyer, MD, Meghan Heberton, MD
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	JAAD Case Reports
Subjects:	angioimmunoblastic T-cell lymphoma immune checkpoint therapy metastatic melanoma pembrolizumab programmed death-1
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512620306986

id	doaj-ad82ea49a92c40879ff2c5dc18cfbd1b
record_format	Article
spelling	doaj-ad82ea49a92c40879ff2c5dc18cfbd1b2020-11-27T04:21:45ZengElsevierJAAD Case Reports2352-51262020-12-0161212641267Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatmentTaylor C. Duke, MD0Ranjit Nair, MD1Carlos Torres-Cabala, MD2Rodabe N. Amaria, MD3Elizabeth Keiser, MD4Roberto Miranda, MD5Swaminathan P. Iyer, MD6Meghan Heberton, MD7Department of Dermatology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TexasDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TexasDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TexasDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TexasDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TexasDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TexasDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TexasDepartment of Dermatology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Correspondence to: Meghan Heberton, MD, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030.http://www.sciencedirect.com/science/article/pii/S2352512620306986angioimmunoblastic T-cell lymphomaimmune checkpoint therapymetastatic melanomapembrolizumabprogrammed death-1
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Taylor C. Duke, MD Ranjit Nair, MD Carlos Torres-Cabala, MD Rodabe N. Amaria, MD Elizabeth Keiser, MD Roberto Miranda, MD Swaminathan P. Iyer, MD Meghan Heberton, MD
spellingShingle	Taylor C. Duke, MD Ranjit Nair, MD Carlos Torres-Cabala, MD Rodabe N. Amaria, MD Elizabeth Keiser, MD Roberto Miranda, MD Swaminathan P. Iyer, MD Meghan Heberton, MD Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment JAAD Case Reports angioimmunoblastic T-cell lymphoma immune checkpoint therapy metastatic melanoma pembrolizumab programmed death-1
author_facet	Taylor C. Duke, MD Ranjit Nair, MD Carlos Torres-Cabala, MD Rodabe N. Amaria, MD Elizabeth Keiser, MD Roberto Miranda, MD Swaminathan P. Iyer, MD Meghan Heberton, MD
author_sort	Taylor C. Duke, MD
title	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
title_short	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
title_full	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
title_fullStr	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
title_full_unstemmed	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
title_sort	angioimmunoblastic t-cell lymphoma associated with immune checkpoint inhibitor treatment
publisher	Elsevier
series	JAAD Case Reports
issn	2352-5126
publishDate	2020-12-01
topic	angioimmunoblastic T-cell lymphoma immune checkpoint therapy metastatic melanoma pembrolizumab programmed death-1
url	http://www.sciencedirect.com/science/article/pii/S2352512620306986
work_keys_str_mv	AT taylorcdukemd angioimmunoblastictcelllymphomaassociatedwithimmunecheckpointinhibitortreatment AT ranjitnairmd angioimmunoblastictcelllymphomaassociatedwithimmunecheckpointinhibitortreatment AT carlostorrescabalamd angioimmunoblastictcelllymphomaassociatedwithimmunecheckpointinhibitortreatment AT rodabenamariamd angioimmunoblastictcelllymphomaassociatedwithimmunecheckpointinhibitortreatment AT elizabethkeisermd angioimmunoblastictcelllymphomaassociatedwithimmunecheckpointinhibitortreatment AT robertomirandamd angioimmunoblastictcelllymphomaassociatedwithimmunecheckpointinhibitortreatment AT swaminathanpiyermd angioimmunoblastictcelllymphomaassociatedwithimmunecheckpointinhibitortreatment AT meghanhebertonmd angioimmunoblastictcelllymphomaassociatedwithimmunecheckpointinhibitortreatment
_version_	1724414280051195904

Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment

Similar Items